Here’s What Hurt Boston Scientific Corporation (BSX) in Q2

3 days ago 3

Soumya Eswaran

Thu, August 13, 2026 astatine 8:14 AM CDT 3 min read

TCW Funds, an concern absorption firm, published its second-quarter 2026 capitalist missive for the 'TCW Concentrated Large Cap Growth Fund.' A transcript of the missive tin beryllium downloaded here. During the 2nd quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve enactment modulation were the important events. All large indices ended higher, driven by resilient economical maturation and beardown firm earnings. April marked a betterment from March lows, with the S&P 500 achieving grounds highs by aboriginal June, mostly owed to robust firm net linked to AI superior spending. Although the money appreciated 14.45% successful the quarter, it trailed the Russell 1000® Growth Index's 16.74% and the S&P 500's 15.20% returns. Holdings successful healthcare and financials wounded comparative results most, portion accusation exertion and user discretionary holdings positively impacted comparative show during the quarter. Please reappraisal the Fund's apical 5 holdings to summation insights into their cardinal selections for 2026.

In its Q2 2026 capitalist letter, TCW Concentrated Large Cap Growth Fund highlighted Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is simply a aesculapian exertion institution that develops, manufactures and markets aesculapian devices for usage successful assorted interventional aesculapian specialties. On August 12, 2026, Boston Scientific Corporation (NYSE:BSX) closed astatine $51.42 per share. One-month instrumentality of Boston Scientific Corporation (NYSE:BSX) was 15.24%, and its shares mislaid 50.63% implicit the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a marketplace capitalization of $74.52 billion.

TCW Concentrated Large Cap Growth Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) successful its Q2 2026 capitalist letter:

"Our weakest comparative show during the 4th came from the healthcare sector. Shares of Boston Scientific Corporation (NYSE:BSX) moved little aft quarterly results and the CHAMPION AF information results. While results modestly bushed expectations, 2 cardinal franchises (U.S. Electrophysiology and Watchman) missed statement and absorption lowered 2026 integrated income maturation guidance to 10 11%. The durability and maturation trajectory for WATCHMAN is simply a absorption for investors, and though CHAMPION-AF information released astatine the extremity of March deed each endpoints, they failed to enactment arsenic a affirmative catalyst for BSX shares. Though we admit the timing and magnitude of WATCHMAN publication whitethorn not beryllium resolved successful the near-term, we judge existent valuation whitethorn person overly discounted the company's semipermanent net maturation profile. Shares stay nether review."

Read Entire Article